THE OPTIMAL DOSE OF RIBAVIRIN FOR CHRONIC HEPATITIS C: FROM LITERATURE EVIDENCE TO CLINICAL PRACTICE

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

ABENAVOLI LUDOVICO; MAZZA MARTA; ALMASIO PIERO L.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Hepatitis Monthly Year:2011 | Volume:11 | Issue:4 (33) Page(s): 240-246

Download Full-Text

View:

384

Download:

237

Cites:

Information Journal Paper

Title

THE OPTIMAL DOSE OF RIBAVIRIN FOR CHRONIC HEPATITIS C: FROM LITERATURE EVIDENCE TO CLINICAL PRACTICE

Author(s)

ABENAVOLI LUDOVICO | MAZZA MARTA | ALMASIO PIERO L. | Issue Writer Certificate

Keywords

HEPATITIS C VIRUS

RIBAVIRIN

DOSE-RESPONSE

Abstract

Approximately 170 million people worldwide are chronically infected by HEPATITIS C VIRUS (HCV), which can result in progressive hepatic injury and fibrosis, culminating in cirrhosis and end-stage liver disease. The benchmark therapy for untreated HCV patients is a combination of pegylated interferon-alpha (PEG-IFN) and RIBAVIRIN (RBV). Several studies have suggested several potential new approaches to improve HCV therapy-optimization of the dose and duration of RBV therapy, accompanied by careful clinical management, is crucial in ensuring the greatest likelihood of a long response to therapy. RBV causes serious side effects, but in clinical practice, there are no alternatives for the treatment of HCV infection. Based on our results, weight-based doses of RBV are advantageous for genotype 1-infected patients, but its success in genotype 2- and 3-infected patients is unknown, particularly for shorter treatment durations.

Cites

No record.

References

No record.

Cite

APA: Copy

ABENAVOLI, LUDOVICO, MAZZA, MARTA, & ALMASIO, PIERO L.. (2011). THE OPTIMAL DOSE OF RIBAVIRIN FOR CHRONIC HEPATITIS C: FROM LITERATURE EVIDENCE TO CLINICAL PRACTICE. HEPATITIS MONTHLY, 11(4 (33)), 240-246. SID. https://sid.ir/paper/306376/en

Vancouver: Copy

ABENAVOLI LUDOVICO, MAZZA MARTA, ALMASIO PIERO L.. THE OPTIMAL DOSE OF RIBAVIRIN FOR CHRONIC HEPATITIS C: FROM LITERATURE EVIDENCE TO CLINICAL PRACTICE. HEPATITIS MONTHLY[Internet]. 2011;11(4 (33)):240-246. Available from: https://sid.ir/paper/306376/en

IEEE: Copy

LUDOVICO ABENAVOLI, MARTA MAZZA, and PIERO L. ALMASIO, “THE OPTIMAL DOSE OF RIBAVIRIN FOR CHRONIC HEPATITIS C: FROM LITERATURE EVIDENCE TO CLINICAL PRACTICE,” HEPATITIS MONTHLY, vol. 11, no. 4 (33), pp. 240–246, 2011, [Online]. Available: https://sid.ir/paper/306376/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops